Evidence map›Paper›PMID 26274523›Full record

ArticleScientific reports2015

Cell-free expression of functional receptor tyrosine kinases.

Wei He, Tiffany M Scharadin, Matthew Saldana, Candice Gellner, Steven Hoang-Phou, Christina Takanishi, Gregory L Hura, John A Tainer, Kermit L Carraway, Paul T Henderson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cationic HDL mimetics enhance in vivo delivery of self-replicating mRNA.Nanomedicine : nanotechnology, biology, and medicine · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Cell-free production of a functional oligomeric form of aThe Journal of biological chemistry · 2017
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Wei HeUniversity of California Davis School of Medicine, Radiation Oncology, Sacramento, California, USA.
Tiffany M ScharadinUniversity of California Davis School of Medicine, Internal Medicine, Division of Hematology Oncology, Sacramento, California, USA.
Matthew SaldanaUniversity of California Davis School of Medicine, Biochemistry and Molecular Medicine, Sacramento, California, USA.
Candice GellnerUniversity of California Davis School of Medicine, Internal Medicine, Division of Hematology Oncology, Sacramento, California, USA.
Steven Hoang-PhouUniversity of California Davis School of Medicine, Radiation Oncology, Sacramento, California, USA.
Christina TakanishiUniversity of California Davis School of Medicine, Internal Medicine, Division of Hematology Oncology, Sacramento, California, USA.
Gregory L Hura1] Lawrence Berkeley National Laboratory, Berkeley, California, USA [2] University of California Santa Cruz, Chemistry and Biochemistry, Santa Cruz, California, USA.
John A Tainer1] Lawrence Berkeley National Laboratory, Berkeley, California, USA [2] Scripps Research Institute, La Jolla, California, USA.
Kermit L Carraway1] University of California Davis School of Medicine, Biochemistry and Molecular Medicine, Sacramento, California, USA [2] University of California Davis Comprehensive Cancer Center, Sacramento, CA California, USA.
Paul T Henderson1] University of California Davis School of Medicine, Internal Medicine, Division of Hematology Oncology, Sacramento, California, USA [2] University of California Davis Comprehensive Cancer Center, Sacramento, CA California, USA.
Matthew A Coleman1] University of California Davis School of Medicine, Radiation Oncology, Sacramento, California, USA [2] University of California Davis Comprehensive Cancer Center, Sacramento, CA California, USA [3] Lawrence Livermore National Laboratory, Livermore, California, USA.
University of California, Davis · USLawrence Berkeley National Laboratory · USUC Davis Comprehensive Cancer Center

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Training Program in Oncogenic Signals and Chromosome BiologyT32CA108459 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HEYER, WOLF-DIETRICH · 2006 to 2020
$3.6M
Characterization of Erbb Receptors in NanoparticlesR01CA155642 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI COLEMAN, MATTHEW ADRIAN, HENDERSON, PAUL THOMAS · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA155642NCI NIH HHS R01-CA155642-01ANCI NIH HHS T32 CA108459
6 · The paper itself

Abstract

Receptor tyrosine kinases (RTKs) play critical roles in physiological and pathological processes, and are important anticancer drug targets. In vitro mechanistic and drug discovery studies of full-length RTKs require protein that is both fully functional and free from contaminating proteins. Here we describe a rapid cell-free and detergent-free co-translation method for producing full-length and functional ERBB2 and EGFR receptor tyrosine kinases supported by water-soluble apolipoprotein A-I based nanolipoprotein particles.

Indexed as

Cell-Free SystemReceptor Protein-Tyrosine KinasesReceptor Protein-Tyrosine Kinases

Identifiers

PMID26274523
PMCPMC4929682
OpenAlexW2419168893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.